コンテンツへスキップ
Merck
すべての画像(1)

主要文書

安全性情報

203389

Sigma-Aldrich

Blebbistatin, Racemic

≥97% (HPLC), liquid, Myosin II inhibitor, Calbiochem®

別名:

InSolutionBlebbistatin, Racemic

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C18H16N2O2
分子量:
292.33
UNSPSCコード:
12352200
NACRES:
NA.77

製品名

Blebbistatin, Racemic, InSolution, ≥97%, 50 mM in 90% DMSO, reversible inhibitor of nonmuscle myosin II

品質水準

アッセイ

≥97% (HPLC)

フォーム

liquid

メーカー/製品名

Calbiochem®

保管条件

OK to freeze
desiccated (hygroscopic)
protect from light

輸送温度

wet ice

保管温度

−20°C

詳細

A cell-permeable compound that acts as a selective, potent, and reversible inhibitor of non-muscle myosin II. Inhibits the ATPase and gliding motility of human platelets (≤100 µM) without affecting myosin light chain kinase (MLCK) activity. Has been shown to block cell blebbing and to rapidly disrupt directed cell migration and cytokinesis in vertebrate cells. Does not disrupt mitosis or affect contractile ring assembly.

生物化学的/生理学的作用

Cell permeable: yes
Primary Target
ATPase
Product does not compete with ATP.
Reversible: yes
Target IC50: <100 µM inhibiting the ATPase and gliding motility of human platelets

包装

Packaged under inert gas

警告

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

物理的形状

A 50 mM (5 mg/342 µl) solution of (±)-Blebbistatin (Cat. No. 203390) in 90% DMSO.

再構成

Following initial thaw, aliquot and freeze (-20°C).

その他情報

Shu, S., et al. 2005. Proc. Natl. Acad. Sci. USA102, 1472.
Kovacs, M., et al. 2004. J. Biol. Chem.279, 35557.
Straight, A.F., et al. 2003. Science299, 1743.
Cheung, A., et al. 2001. Mol. Biol. Cell Suppl.12, 271a.

法的情報

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類コード

10 - Combustible liquids

WGK

WGK 1

引火点(°F)

188.6 °F - closed cup - (Dimethylsulfoxide)

引火点(℃)

87 °C - closed cup - (Dimethylsulfoxide)


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

消防法

第4類:引火性液体
第三石油類
危険等級III
非水溶性液体

Jan Code

203389-5MG:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Martin S Weiß et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(19), e2305947-e2305947 (2024-03-13)
Tissue homeostasis and disease states rely on the formation of new blood vessels through angiogenic sprouting, which is tightly regulated by the properties of the surrounding extracellular matrix. While physical cues, such as matrix stiffness or degradability, have evolved as
Kevin X Lau et al.
Nature communications, 11(1), 2420-2420 (2020-05-18)
Archetypal human pluripotent stem cells (hPSC) are widely considered to be equivalent in developmental status to mouse epiblast stem cells, which correspond to pluripotent cells at a late post-implantation stage of embryogenesis. Heterogeneity within hPSC cultures complicates this interspecies comparison.
Catarina Domingues et al.
Frontiers in cell and developmental biology, 8, 678-678 (2020-09-10)
The mechanical properties of the extracellular environment are interrogated by cells and integrated through mechanotransduction. Many cellular processes depend on actomyosin-dependent contractility, which is influenced by the microenvironment's stiffness. Here, we explored the influence of substrate stiffness on the proteome
Cell segregation via differential collision modes between heterotypic cell populations.
Lucia, et al.
Molecular Biology of the Cell, 33, ar129-ar129 (2023)
Lawrence J Dooling et al.
Nature biomedical engineering, 7(9), 1081-1096 (2023-04-25)
In solid tumours, the abundance of macrophages is typically associated with a poor prognosis. However, macrophage clusters in tumour-cell nests have been associated with survival in some tumour types. Here, by using tumour organoids comprising macrophages and cancer cells opsonized

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)